New Investor Presentation Uploaded on 8 Sep. ht
Post# of 148302
https://www.cytodyn.com/newsroom/presentations
Here are the updates that I found between this one and the previous one from 26 August.
1) 350 mg responder rate increased 1% from 70% to 71%
2) 700 mg responder rate decreased 1% from 88% to 87% from 19 weeks to 20 weeks
3) Revenue potential changed to '1H2020' from '2020'
4) 'GvHD Interim Results 1Q2020' changed to 'GvHD First Patient Injected 4Q2019'
5) Some 1H/2H were dropped from 2019 (no change since we are in 2H already).